Olvimulogene nanivacirepvec Medicine 04 December 2025 Extended indication Olvimulogene nanivacirepvec in combination with platinum-doublet chemotherapy and bevacizumab for fourth line or later treatment of platinum-resistant/refractory, high-grade serous, non-resectable Fallopian tube cancer, Ovarian cancer, Primary peritoneal carcinosarcoma in adults and elderly. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Olvimulogene nanivacirepvec Domain Oncology Reason of inclusion New medicine (specialité) Main indication Ovarian cancer Extended indication Olvimulogene nanivacirepvec in combination with platinum-doublet chemotherapy and bevacizumab for fourth line or later treatment of platinum-resistant/refractory, high-grade serous, non-resectable Fallopian tube cancer, Ovarian cancer, Primary peritoneal carcinosarcoma in adults and elderly. Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Genelux Portfolio holder Genelux Mechanism of action Route of administration Intraperitoneal Therapeutical formulation Unknown Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity ATMP Yes Submission date June 2026 Expected Registration July 2027 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Non-platinum monotherapie, eventueel in combinatie met bevacizumab. Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation De studie includeert nog tot september 2025. Er zijn nog geen resultaten beschikbaar. Duration of treatment Frequency of administration Dosage per administration References NCT05281471 (OnPrime, GOG-3076) Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References IKNL 2024 (1) Additional remarks In Nederland worden jaarlijks ongeveer 1.300 nieuwe gevallen van hooggradige serieuze ovarium-, tuba- en primaire peritoneale carcinosarcoom vastgesteld (1). Hiervan is een deel platinum-resistent, waarbij slechts een klein deel geschikt is voor een vierdelijns of latere behandeling. Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks